A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.
LT-02-19
Phase 1 other active
Quick answer
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY. for Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps is a Phase 1 program (other) at Laboratorios Tillomed Spain S.L.U with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Laboratorios Tillomed Spain S.L.U
- Indication
- Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps
- Phase
- Phase 1
- Modality
- other
- Status
- active